BioScrip Announces Availability of HEMLIBRA® for Hemophilia Patients

DENVER, Jan. 08, 2018 -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that it can now dispense and administer HEMLIBRA® (emicizumab-kxwh), a U.S. Food and Drug Administration (FDA) approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. HEMLIBRA® is commercialized in the U.S. by Genentech USA, Inc.

"BioScrip continues to expand our therapy offering to better care for the patients we support," said Robert Roose, Senior Vice President and Chief Procurement Officer. "Receiving the approval to dispense and administer HEMLIBRA® underscores the fact that BioScrip is a destination of choice for our manufacturers."

BioScrip will provide HEMLIBRA® in the patient’s home or in an infusion suite setting, depending on the patient’s care plan and condition. These capabilities include providing the first dose of HEMLIBRA® where the patient’s care plan permits. BioScrip will assist caregivers and patients to be independent with HEMLIBRA® therapy in the comfort of their own home, when approved by the prescriber. Prescribers may find a list of BioScrip’s infusion pharmacies and infusion suites by visiting the Company’s website at www.bioscrip.com.

HEMLIBRA® is administered through subcutaneous injection of 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly. HEMLIBRA® is intended for use under the guidance of a healthcare provider. After proper training in subcutaneous injection technique, a patient may self-inject, or the patient’s caregiver may administer HEMLIBRA®, if a healthcare provider determines that it is appropriate.

About BioScrip, Inc.

BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Important Safety Information

WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM

Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of > 100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA® prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA® if symptoms occur.

Warnings and Precautions                                                                 

• Laboratory coagulation test interference: HEMLIBRA® interferes with activated clotting time (ACT), activated partial thromboplastin time (aPTT) and coagulation laboratory tests based on aPTT, one-stage aPTT-based single-factor assays, aPTT-based Activated Protein C Resistance (APC-R), and Bethesda assays (clotting-based) for factor VIII (FVIII) inhibitor titers. Intrinsic pathway clotting-based laboratory tests should not be used.

Most Common Adverse Reactions

The most common adverse reactions (incidence rate ≥ 10%) were injection site reactions and headache, and arthralgia.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional Important Safety Information, including Boxed WARNING, or go to https://www.gene.com/download/pdf/hemlibra_prescribing.pdf.

Contact:

Robert Roose
Senior Vice President, Chief Procurement Officer
T: (720) 697-5179